—
Niner Pharmaceuticals LLC, a leading pharmaceutical company, first in the GCC region, has launched two problem-solving products, Ninervilda-50 (vildagliptin 50 mg) and Vertephin(Verteporfin), targeted at addressing critical blood vessel disorders in the eye. These innovations are set to upgrade the treatment of macular degeneration and other related diseases in the UAE, Saudi Arabia, and Latino-American countries, marking the company's pioneering entry into the GCC region with these advanced solutions.
Verteporfin, an essential component in these treatments, enhances the eye's sensitivity to light, offering a new ray of hope for patients suffering from vision-threatening conditions. In conjunction with "photodynamic" laser light therapy, it presents a formidable approach to managing abnormal blood vessel activity within the eye.
"In our journey to bring transformative healthcare solutions to the forefront, we are proud to introduce Ninervilda-50 and Vertephin. These products embody our commitment to innovation, quality, and global reach, ensuring that critical healthcare solutions are within reach of those in need," stated Mr Jami Balaji Rao, Founder and CEO of Niner Pharmaceuticals.
He further added, "Our focus is not just on treating conditions but on upgrading how care is delivered, making promising strides towards a healthier tomorrow."
Niner Pharmaceuticals is reshaping the healthcare industry through digital transformation. The upcoming Niner MedTech application exemplifies this by facilitating virtual interactions between doctors and patients, transcending geographical barriers and setting a new standard in medical care.
By leveraging innovative research and development and embracing digital transformation, Niner Pharmaceuticals is not only addressing today's healthcare challenges but also paving the way for the industry's future.
Contact Info:
Name: Jamie Balaji Rao
Email: Send Email
Organization: Niner Pharmaceuticals LLC
Website: https://www.ninerpharma.com/
Release ID: 89127927
Google
RSS